Doxofylline is a novel bronchodilator. It structurally differs from Theophylline due to the presence of a dioxolane group in position 7. Doxofylline selectively inhibits phosphodiesterase-4 thereby relaxes bronchial smooth muscle. However, differently from Theophylline, Doxofylline appears to have decreased affinities toward adenosine A1 and A2 receptors, which may account for the better safety profile of the drug. Doxofylline is reported to inhibit platelet activating factor (PAF) and generation of leukotriene production.